Tag Archives: Against

Clovis investors lose faith as Rubraca struggles against Big Pharma’s marketing giants

It’s no secret that Clovis Oncology is up against some serious marketing muscle in the PARP inhibitor arena. And investors are doubting the company’s ability to hang in there. Shareholders headed for the exits Thursday after Clovis reported that Rubraca sales tallied just $ 33 million in the second quarter, coming in $ 2 million… Read More »

A Judge Rules Against One Stem-Cell Clinic. There Are Hundreds of Them.

A judicial ruling this month that will stop questionable stem-cell treatments at a clinic in Florida is widely seen as a warning to a flourishing industry that has attracted huge numbers of patients, who pay thousands of dollars for unproven, risky procedures. But with little regulatory oversight for the hundreds of clinics operating these lucrative… Read More »

Improved stem cell approach could aid fight against Parkinson’s

Scientists have taken a key step towards improving an emerging class of treatments for Parkinson’s disease. The advance could markedly improve a next generation of therapies for the condition, which affects around one in 350 people in the UK. It could aid development of the promising treatment-; known as cell replacement therapy -; which was… Read More »